A Nature Communications study described engineered nanovesicles that target the m6A writer METTL3 to curb neuroinflammation in cell and animal models. The work from Xu, Pan, Li and colleagues focused on neuroinflammatory activation as a cross-disease driver in settings ranging from neurodegeneration to viral central nervous system injury. The strategy matters because it couples targeted epitranscriptomic modulation (m6A) with delivery via nanovesicles—an intersection that could expand options beyond broad anti-inflammatory approaches. The next step for the field will be assessing dosing, biodistribution, and translational safety markers.